323 related articles for article (PubMed ID: 15690188)
1. Are new vitamin D analogues in renal bone disease superior to calcitriol?
Salusky IB
Pediatr Nephrol; 2005 Mar; 20(3):393-8. PubMed ID: 15690188
[TBL] [Abstract][Full Text] [Related]
2. Calcitriol and doxercalciferol are equivalent in controlling bone turnover, suppressing parathyroid hormone, and increasing fibroblast growth factor-23 in secondary hyperparathyroidism.
Wesseling-Perry K; Pereira RC; Sahney S; Gales B; Wang HJ; Elashoff R; Jüppner H; Salusky IB
Kidney Int; 2011 Jan; 79(1):112-9. PubMed ID: 20861820
[TBL] [Abstract][Full Text] [Related]
3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
4. Vitamin D analogues for the management of secondary hyperparathyroidism.
Martin KJ; González EA
Am J Kidney Dis; 2001 Nov; 38(5 Suppl 5):S34-40. PubMed ID: 11689385
[TBL] [Abstract][Full Text] [Related]
5. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
6. Prevention of metabolic bone disease in the pre-end-stage renal disease setting.
Coburn JW; Elangovan L
J Am Soc Nephrol; 1998 Dec; 9(12 Suppl):S71-7. PubMed ID: 11443772
[TBL] [Abstract][Full Text] [Related]
7. Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals.
Kalantar-Zadeh K; Shah A; Duong U; Hechter RC; Dukkipati R; Kovesdy CP
Kidney Int Suppl; 2010 Aug; (117):S10-21. PubMed ID: 20671739
[TBL] [Abstract][Full Text] [Related]
8. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
Lorenzo Sellares V; Torregrosa V
Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742
[TBL] [Abstract][Full Text] [Related]
9. Strategies to minimize bone disease in renal failure.
Martin KJ; González EA
Am J Kidney Dis; 2001 Dec; 38(6):1430-6. PubMed ID: 11728986
[TBL] [Abstract][Full Text] [Related]
10. Role of parathyroid hormone and therapy with active vitamin D sterols in renal osteodystrophy.
Hernandez JD; Wesseling K; Salusky IB
Semin Dial; 2005; 18(4):290-5. PubMed ID: 16076350
[TBL] [Abstract][Full Text] [Related]
11. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy.
Goodman WG; Ramirez JA; Belin TR; Chon Y; Gales B; Segre GV; Salusky IB
Kidney Int; 1994 Oct; 46(4):1160-6. PubMed ID: 7861712
[TBL] [Abstract][Full Text] [Related]
12. Prevention and treatment of renal osteodystrophy in children with chronic renal insufficiency and end-stage renal disease.
Sanchez CP
Semin Nephrol; 2001 Sep; 21(5):441-50. PubMed ID: 11559885
[TBL] [Abstract][Full Text] [Related]
13. Renal osteodystrophy in chronic renal failure.
Ho LT; Sprague SM
Semin Nephrol; 2002 Nov; 22(6):488-93. PubMed ID: 12430093
[TBL] [Abstract][Full Text] [Related]
14. [Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient].
Brancaccio D; Cozzolino M; Galassi A; Bellasi A; Carpani P; Gallieni M
G Ital Nefrol; 2003; 20 Suppl 22():S12-6. PubMed ID: 12851915
[TBL] [Abstract][Full Text] [Related]
15. Osteopenia during long-term haemodialysis: response to vitamin D3 analogues.
Muirhead N; Adami S; Fraser RA; Catto GR; Edward N; O'Riordan JL
Proc Eur Dial Transplant Assoc; 1981; 18():567-72. PubMed ID: 6895786
[No Abstract] [Full Text] [Related]
16. Vitamin D analogues for secondary hyperparathyroidism.
Brown AJ; Dusso AS; Slatopolsky E
Nephrol Dial Transplant; 2002; 17 Suppl 10():10-9. PubMed ID: 12386264
[TBL] [Abstract][Full Text] [Related]
17. Renal osteodystrophy: role of calcimimetics.
Hörl WH
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S104-7. PubMed ID: 12612964
[TBL] [Abstract][Full Text] [Related]
18. Effects of treatment of renal osteodystrophy on bone histology.
Malluche HH; Mawad H; Monier-Faugere MC
Clin J Am Soc Nephrol; 2008 Nov; 3 Suppl 3(Suppl 3):S157-63. PubMed ID: 18988701
[TBL] [Abstract][Full Text] [Related]
19. [Role of diet in the management of osteodystrophy during progressive renal insufficiency].
Martínez I; Saracho R; Ocharán J; Muñoz RI; Montenegro J
Nefrologia; 2003; 23 Suppl 2():57-63. PubMed ID: 12778856
[TBL] [Abstract][Full Text] [Related]
20. Vitamin D, vitamin D receptor and the importance of its activation in patients with chronic kidney disease.
Bover J; Egido J; Fernández-Giráldez E; Praga M; Solozábal-Campos C; Torregrosa JV; Martínez-Castelao A
Nefrologia; 2015; 35(1):28-41. PubMed ID: 25611831
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
